Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma.
Recombinant activated factor VII (rFVIIa) (NovoSeven; Novo Nordisk A/S, Bagsvaerd, Denmark) is a haemostatic agent first developed for bleeding associated with haemophilia and trauma, but for which the indications continue to expand. Recent reports have suggested efficacy for various types of intracranial haemorrhage and for patients with abnormalities of coagulation. We report a warfarin-anticoagulated Jehovah's Witness patient with an acute subdural haematoma for whom rFVIIa was used perioperatively. The haematoma was surgically evacuated without excessive blood loss and the patient eventually made a good recovery, returning to independent self-care.
Goldberg
Rimma
R
Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.
Drummond
Katharine J
KJ
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D003029:Coagulants / Q000627:therapeutic use*; D005167:Factor VII / Q000627:therapeutic use*; D005260:Female; D020199:Hematoma, Subdural, Acute / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D006801:Humans; D033221:Jehovah's Witnesses; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D003029:Coagulants; D011994:Recombinant Proteins; D014859:Warfarin; D005167:Factor VII